Optimizing Pfizer’s Digital Evolution

From Molecule to Market with BIOVIA

In a global organization of Pfizer’s scale, the challenge isn't just digitizing—it’s unifying. To truly accelerate the next breakthrough, your data must flow seamlessly across your organization, from biotherapeutics and small molecule development to manufacturing.

BIOVIA offers the only scientific platform engineered to handle this complexity. With BIOVIA you can access a unified digital backbone designed for the specific rigors of drug process development and tech transfer.

Simplify the Scientist's Daily Work

We understand the nuances of biotherapeutics and small-molecule development. Our platform is designed to:

Streamline Workflows

Eliminate Data Silos > Dassault Systèmes®

Eliminate Data Silos

Connect disparate workflows into one cohesive digital thread

Ensure Compliance > Dassault Systèmes®

Ensure Compliance

Maintain a rigorous, audit-ready environment without sacrificing agility

Accelerate Tech Transfer > Dassault Systèmes®

Accelerate Tech Transfer

Standardize process definitions to move molecules from the lab to the plant faster than ever before

BIOVIA is uniquely equipped to optimize Pfizer's complex requirements. We stand alone in our ability to provide a scientific digital platform that supports the entire molecule-to-manufacturing lifecycle within a single, compliant environment.

Want to learn more? Download our e-book "Moving Beyond LIMS"